GSK plc stands to be the first to submit Phase III data to regulators for use of a respiratory syncytial virus (RSV) vaccine in adults 50-59, potentially broadening the adult market opportunity for the vaccine. Arexvy received US Food and Drug Administration approval in May for adults 60 and older almost simultaneously with Pfizer Inc.’s RSV vaccine Abrysvo. The vaccines are the first to reach the market for RSV lower respiratory tract disease, putting the two companies in a competitive commercial showdown.
In Competitive RSV Market, GSK Aims To Be First For Adults 50-59
Results from a Phase III trial testing the RSV vaccine Arexvy in adults 50-59 met the two primary endpoints, potentially opening the door to a wider adult market.
